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Abstract
Purpose The primary hypothesis to be tested in this study
was that the diagnostic performance (as assessed by the
area under the receiver operator characteristic curve, AUC)
of a multianalyte panel to correctly identify women with
ovarian cancer was signiWcantly greater than that for CA-
125 alone.
Methods A retrospective, case–control study (phase II bio-
marker trial) was conducted that involved 362 plasma sam-
ples obtained from women with ovarian cancer (n = 150)
and healthy controls (n = 212). A multivariate classiWcation
model was developed that incorporated Wve biomarkers of
ovarian cancer, CA-125; C-reactive protein (CRP); serum
amyloid A (SAA); interleukin 6 (IL-6); and interleukin 8
(IL-8) from a modelling cohort (n = 179). The performance
of the model was evaluated using an independent validation
cohort (n = 183) and compared with of CA-125 alone.
Results The AUC for the biomarker panel was signiW-
cantly greater than the AUC for CA-125 alone for a valida-
tion cohort (p < 0.01) and an early stage disease cohort (i.e.
Stages I and II; p < 0.01). At a threshold of 0.3, the sensitiv-
ity and speciWcity of the multianalyte panel were 94.1 and
91.3%, respectively, for the validation cohort and 92.3 and
91.3%, respectively for an early stage disease cohort.
Conclusions The use of a panel of plasma biomarkers for
the identiWcation of women with ovarian cancer delivers a
signiWcant increase in diagnostic performance when com-
pared to the performance of CA-125 alone.
Keywords Ovarian cancer · Diagnostic · Multivariate 
classiWcation
Abbreviations
CRP C-reactive protein
SAA Serum amyloid A
IL-6 Interleukin-6
IL-8 Interleukin-8
ROC Receiver operator characteristic curve
AUC Area under ROC-curve
LD Limit of detection
CV CoeYcient of variation
Introduction
Ovarian cancer continues to be the leading cause of death
among women with gynaecological malignancies in devel-
oped nations (Parkin et al. 2005). In the USA, the preva-
lence of ovarian cancer in postmenopausal women is 1 in
2,500 and the lifetime risk of a woman developing ovarian
cancer is 1 in 72 (1.39%). The age-adjusted incidence and
death rates for ovarian cancer are 13.3 and 8.8 per 100,000,
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respectively. The overall 5-year survival rate is 45.5%.
Five-year survival rates are inversely related to the stage of
disease at Wrst diagnosis. Early stage ovarian cancer is
asymptomatic and only 19% of cases are Wrst diagnosed as
localised primary cancer (i.e. Stage I). The corresponding
5-year survival rate for Stage I disease is 92.7%. The
majority of cases (67–74%), however, are diagnosed with
metastatic disease (i.e. Stages III and IV), when the 5-year
survival rate is only 30.6% (Ries et al. 2006).
The diagnosis of localised, primary cancer and the
development of tests with better diagnostic eYciency are
undoubtedly the major priorities for achieving long-term
reduction of mortality due to ovarian cancer (Paley 2001).
Indeed, available data support the hypothesis that ovarian
cancers may be detectable up to 2–5 years prior to their
clinical presentation (Jacobs et al.  1993,  1996,  1999;
Zurawski et al.  1988) and that if eVective screening for
Stage I disease was achieved with an accuracy of 80% or
more, mortality would be halved (Bast et al. 1983). The
development of eVective community-based screening
or earlier detection tests for ovarian cancer, however, is
challenging because of the low prevalence of the disease
(Parkin et al. 2005).
The most well-characterised biomarker for ovarian can-
cer is CA-125 (Nossov et al. 2008). Serum concentrations
of CA-125 are elevated (i.e. >35 U/ml) in more than 90%
of patients with late stage disease but are elevated in only
50% of patients with Stage I disease (Nustad et al. 1996). It
is becoming evident that the single biomarker approaches
for the detection of early stage ovarian cancer may never
realise the diagnostic eYciency requisite for implementa-
tion as a community-based screening and alternate
approaches, including the combination of multiple bio-
markers may be required (Badgwell and Bast 2007).
The quantiWcation of multiple blood-borne biomarkers
and the use of multivariate classiWcation models represent a
promising approach for improving diagnostic eYciency.
Such biomarkers may represent: unique tumour-derived or
over-expression products; products elaborated via aberrant
neoplastic processing/modiWcation of host proteins; and/or
host response proteins elicited by the presence of the
tumour and which may display proWles that vary and/or are
speciWc for diVerent types of tumours.
Previous studies have established proof-of-principle and
reported signiWcant improvements in the detection of ovar-
ian cancer using such approaches. For example, Gorelik
et al. (2005) measured seven serum biomarkers in 44 newly
diagnosed women with early stage ovarian cancer (i.e.
Stages 1 and II) and 45 healthy controls and employed Wve
of the biomarkers (including CA-125) in a classiWcation
tree analysis to achieve a sensitivity of 84% at a speciWcity
of 95% for the detection of early stage disease. More
recently, Visintin et al. ( 2008) in a study of 156 newly
diagnosed ovarian cancer patients (48 Stage I, 62 Stage II,
64 Stage III and 64 Stage IV) and 362 healthy women
utilised six serum biomarkers (including CA-125) in a
multivariate classiWcation model and reported a sensitivity
and speciWcity of 95.3 and 99.4%, respectively, for the
overall detection of ovarian cancer.
To further evaluate the utility of a multimarker
approach for the diagnosis of ovarian cancer, in this study
a phase II biomarker trial (Pepe et al.  2001) was con-
ducted to evaluate the performance of a panel of plasma
biomarkers (CA-125, CRP, IL-6, IL-8 and SAA) to cor-
rectly classify women with ovarian cancer. The retrospec-
tive, case–control, modelling/validation study was
designed to test the primary hypothesis that the area under
the receiver operator characteristic curve (AUC) for the
biomarker panel was signiWcantly greater than the AUC
for CA-125 alone. The data were additionally stratiWed to
assess the performance of the biomarker panel to correctly
classify women with early stage ovarian cancer (i.e.
Stages I and II).
Materials and methods
Sample collection
Blood (10 ml) was collected via vena puncture into EDTA
vacutainer tubes. Samples were centrifuged at 1,000£g for
10 min within 20–30 min of collection. Plasma was stored
as 250–500 l aliquots and stored at ¡80°C until assayed.
All plasma samples analysed were not stored for greater
than 6 years. In a preliminary study, analyte concentrations
were found not to correlate signiWcantly with duration of
storage. Additional disease and control samples were pro-
vided by the Biobank at Peter MacCallum Cancer Research
Institute. Samples were randomly selected from the sample
bank. Inclusion and exclusion criteria into the trial are
detailed in Table 1. The distribution of samples by disease
stage, tumor type and patient age are summarised in
Table 2.
Study design
A phase II biomarker trial design (Pepe et al. 2001) was
employed to assess the diagnostic eYciency of a biomarker
panel for the detection of ovarian cancer. The study was a
retrospective, case–control design in which a multivariate
classiWcation model was developed using a modelling sam-
ple cohort, n =1 7 9  ( T a b l e3). The multivariate classiWca-
tion model (diagnostic rule) was validated using an
independent sample cohort (n = 183). The primary outcome
of the study was to test the hypothesis that the area under
the received operator characteristic (ROC) curve for theJ Cancer Res Clin Oncol (2010) 136:1079–1088 1081
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biomarker panel (AUCA) was signiWcantly greater than for
CA-125 alone (AUCC). It is acknowledged that most infor-
mative biomarkers will increase the AUC by 0.05 or more,
and that good risk prediction models will have an AUC
greater than 0.7 (May and Wang 2008). Secondary out-
comes of the study were: (1) to estimate the sensitivity and
speciWcity of the multimarker panel; and (2) to determine
the relationship between the predicted posterior probability
for membership of the disease class (P, derived from
multivariate modelling) and disease stage and type. The
performance of the diagnostic rule was also evaluated using
a subset of the validation cohort: all controls + Stages I and
II cases only, designated the early stage cohort.
Sample processing
Where necessary plasma samples were diluted appropri-
ately for each assay according to manufacturers, speciWca-
tions using a phosphate buVer containing bovine serum
albumin (Sigma, St. Louis, MI, USA). In brief, for IL-6 and
IL-8 assays, plasma samples were diluted 1:4, and for SAP,
SAA and CRP assays plasma samples were diluted 1:2,000.
Plasma CA-125 concentrations were assayed without prior
dilution.
Frozen plasma samples and dilutions were thawed on ice
prior to assay. All assays were performed in accordance
with manufacturers’ instructions. All assays contained sup-
plied standard curve samples of known analyte concentra-
tion. All standards, controls and patient samples were
assayed in duplicate. Upon completion of each multiplex
assay, a 5-parameter Wt equation was employed to generate
standard curves, from which mean values for each sample
were calculated.
Table 1 Criteria for inclusion and exclusion in the Phase II biomarker trial
Inclusion criteria Exclusion criteria
Age 18–90 Chemotherapy, biologic therapy or any other investigational 
drug for any reason within 28 days prior to sampling
Newly diagnosed, pathologically conWrmed 
diagnosis of epithelial carcinoma of the ovary
Except for cancer-related abnormalities, patients should 
not have unstable or pre-existing major medical conditions
No NSAID or anti-inXammatory steroids 
used within 14 days of sampling
Major surgical procedure, open biopsy, or signiWcant traumatic 
injury within 28 days prior to sampling
No previous chemotherapy or radiation therapy Minor surgical procedures, Wne needle aspirations or core biopsies 
within 7 days prior to sampling
No concurrent disease(s) Serious, non-healing wound or ulcer
Signed informed client consent
Table 2 Age, stage and tumour type distribution within the all cases (n = 150)
Cases Stage 1 Stage II Stage III Stage IV Unstaged Total %
Age Mean § SE 
Median (range)
59 § 1.8 
56 (41–79)
60 § 1.7 
61 (24–85)
57 § 2.0 
57.5 (18–89)
66 § 4.0 
66 (51–59)
53 § 4.3 
53 (38–69)
59 § 1.0 
58 (18–89)
Serous carcinoma 10 41 38 7 3 99 66.0
Endometroid carcinoma 6 6 3 15 10.0
Mucinous carcinoma 5 3 3 11 7.3
Clear cell carcinoma 1 6 1 3 11 7.3
Mixed carcinoma 3 3 6 4.0
Untyped carcinoma 3 4 1 8 5.3
Total 28 63 46 7 6 150
% 18.7 42.0 30.7 4.7 4.0
Table 3 Sample distribution between the model and validation
cohorts
In all analyses, the modelling cohort remained constant
The validation cohorts submitted to the algorithm generated from the
modelling cohort were: (i) the all stage validation cohort; and (ii) the
early stage cohort
Cohort Total Controls Cases Early stage Late stage
a. All stages
Modelling 179 97 82 52 30
Validation 183 115 68 39 29
b. Early stages
Modelling 179 97 82 52 30
Early stage 154 115 39 39 01082 J Cancer Res Clin Oncol (2010) 136:1079–1088
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Biomarker quantiWcation
Multiplexed bead-based assays were used to measure all
analytes on a Biorad Bioplex 100 platform, with the excep-
tion of CA-125, which was assayed using a Roche modular
E170. Multiplexed interleukin-6 and interleukin-8 assays
(BioPlex®) were obtained from Bio-Rad Laboratories,
Hercules, CA, USA and data are reported as pg/ml
(LD = 10 pg/ml, intra- and inter-assay CV = <15 and
<30%, respectively). Multiplexed serum amyloid A (SAA,
ng/ml, LD = 0.2 pg/ml, intra- and inter-assay CV = 3.8 and
<19.8%, respectively) and C-reactive protein (CRP g/ml,
LD = 6 pg/ml, intra- and inter-assay CV = 8.0 and <17.5%,
respectively) assays were obtained from Millipore (Bille-
rica, MA, USA). CA-125 was quantiWed using Roche
CA-125 Elecsys II assay (Roche, Mannheim, Germany,
LD = 0.6 U/ml; intra- and inter-assay coeYcients of varia-
tion CV = 3.3 and 4.3%).
Statistical analysis
Statistical analyses, model development and samples classi-
Wcations were performed by an independent biostatistian
(Emphron Informatic Pty Ltd., Toowong, QLD, Australia).
The primary outcome of the Phase II biomarker trial was
the statistical comparison (Wilcoxon statistic (Waegeman
et al. 2008), see below) of the area under the curve of the
ROC curves for the biomarker panel and CA-125. Two
sample group comparisons of median values were assessed
by Mann–Whitney tests. Multiple group comparisons were
assessed by Kruskal–Wallis tests (Kruskal and Wallis
1952). Dunn’s tests (Dunn 1964) were used for post hoc
two sample comparisons. A p value of <0.05 was ascribed
as statistically signiWcant.
Modelling
As previously described, all samples (n = 362) were ran-
domly assigned to two cohorts: the Wrst was designated as
the modelling cohort (n = 179) from which a classiWcation
algorithm was generated; and the second as the validation
cohort (n = 183) which was used to establish the perfor-
mance of the classiWcation algorithm. A multivariate classi-
Wcation model was developed, based upon biomarker data
obtained from the modelling cohort, using a stochastic gra-
dient boosting model with a logistic loss function as previ-
ously described (Friedman et al.  2000). The boosted
logistic regression algorithm was implemented within the
R statistical programming environment (Team 2003). The
implemented classiWcation algorithm reported a predicted
posterior probability value (i.e. the likelihood that a sample
came from a woman with ovarian cancer, that is P) for
each patient sample. P values were used to generate ROC
curves for the biomarker panel. Biomarker data obtained
from the validation cohort and the early stage cohorts were
submitted to the classiWcation algorithm to establish diag-
nostic eYciency (i.e. the proportion of samples correctly
classiWed by the modelling algorithm). For classiWcation of
samples based on plasma CA-125 concentrations, a thresh-
old value of ¸35 U/ml was used. A threshold value of 0.3
was used for the classiWcation of samples based on P.
Receiver operator characteristic curve comparisons
The diagnostic performance of the biomarker panel and CA-
125 alone were assessed by comparison of the area under
ROC curves (Hanley and McNeil 1982). The ROC curve for
the biomarker panel was based on P values. The area under
the ROC curve (AUC) was calculated using the Wilcoxon
statistic (Waegeman et al. 2008). As the AUC for the CA-
125 and for the biomarker panel are not statistically indepen-
dent, since they are based on the same patients, the diVerence
in AUC between the diagnostics were statistically assessed
using a bootstrap procedure (Efron 1986). The number of
bootstrap samples used in this analysis was n = 100,000. The
estimators considered were the area under the ROC curve as
well as the diVerence between the AUCs, and the measures
of accuracy were the 95% conWdence intervals.
Results
Cohort characteristics; variation in plasma biomarker 
concentrations with patient age, disease state, stage, 
and tumour type
The age distribution of the case cohort (overall and by dis-
ease stage) is presented in Table 2. The median age (range)
of the control cohort (n = 212) was 49 (20–89) years
(mean § SE, 47 § 0.8). Within case and control cohorts,
no eVect of age on plasma biomarker concentration was
identiWed (Spearman’s rank correlation using the Bonfer-
roni correction, p > 0.05), with the exception of SAA in the
control cohort ( = 0.243, p = 0.005, n = 212).
The variation in biomarker plasma concentrations for
controls, all cases of ovarian cancer and early stage (i.e.
Stages I and II) ovarian cancer are presented in Fig. 1. The
median concentration of all biomarkers was signiWcantly
greater in both case cohorts (i.e. validation and early stage)
than in the control cohort (p < 0.001, as assessed by Mann–
Whitney tests) (Table 4). No signiWcant diVerences in bio-
marker plasma concentrations were identiWed between the
modelling (n = 179) and validation (n = 183) cohorts
(p > 0.05). No statistically signiWcant eVects of duration of
sample storage at ¡80°C could be identiWed for any analyte
(data not shown).J Cancer Res Clin Oncol (2010) 136:1079–1088 1083
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The cut-oV value for CA-125 plasma concentration was
¸35 U/ml in 7.6% of control samples (i.e. 16 false positive
cases). Within the case cohort, CA-125 plasma concentra-
tion was less than 35 U/ml in 8.7% of samples (i.e. 13 false
negative cases) and 60.7% of case samples (i.e. 91 cases)
were early stage disease (Stages I and II). Within early
stage cases, CA-125 plasma concentration was <35 U/ml in
12.1% (i.e. 11 false negative cases). CA-125 was elevated
(i.e. ¸35 U/ml) in 75% of Stage I, 93.7% of Stage II and
98.1% of Stage III/IV cases. Data were further analysed
with respect to tumour type (i.e. serous, n = 99, clear cell,
n = 15), endometrioid (n = 11), mucinous (n =1 1 )  a n d
Fig. 1 Variation in biomarker plasma concentrations presented as
scatter plots and median values for controls (n = 212), all cases of
ovarian cancer (n = 150) and early stage ovarian cancer (Stages I
and II, n =9 1 ) . CA-125 U/ml; CRP g/ml; SAA ng/ml; IL-6 and
IL-8 pg/ml
Table 4 Biomarker plasma concentrations
Data are presented as mean § SE and median (range). Two-sample comparisons of case versus control for all biomarkers are signiWcantly diVerent
(p < 0.01, Mann–Whitney tests)
Biomarker Controls (n = 212) Cases (n = 150) Early stage 
(Stages I and II) (n =9 1 )
CA-125 (U/ml) Mean § SE 19 § 1 1,419 § 258 1,008 § 180
Median (range) 14 (3–157) 511 (5–24,459) 499 (5–10,761)
CRP (g/ml) Mean § SE 11 § 18 8 § 99 7 § 14
Median (range) 5 (0–115) 60 (1–500) 63 (1–500)
SAA (ng/ml) Mean § SE 5 § 1 113 § 14 118 § 18
Median (range) 2 (0–98) 14 (0–500) 12 (0–500)
IL-6 (pg/ml) Mean § SE 31 § 96 2 § 11 77 § 17
Median (range) 5 (0–1,799) 24 (1–1,488) 35 (1–1,488)
IL-8 (pg/ml) Mean § SE 42 § 19 138 § 42 197 § 69
Median (range) 4 (0–4,091) 46 (0–5,608) 70 (0–5,608)1084 J Cancer Res Clin Oncol (2010) 136:1079–1088
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mullerian mixed type (mixed, n = 6). Tumour typing was
not available for eight samples. No signiWcant eVect of
tumour type on biomarker plasma concentrations was iden-
tiWed (Kruskal–Wallis one-way analysis of variance,
p >0 . 0 5 ) .
Multivariate modelling and ROC curve comparisons
A binomial classiWcation model was developed by subject-
ing the observed plasma concentrations for each of the Wve
biomarkers within the modelling cohort to stochastic gradi-
ent boosted logistic regression analysis (Friedman et al.
2000). The algorithm (diagnostic rule) generated was
implemented within the R statistical environment and its
diagnostic eYciency evaluated using the independent vali-
dation cohort (n = 183, controls = 115, cases = 68). A P
was calculated for each patient’s set of biomarkers and used
to generate the model ROC curve (Fig. 2). The variation in
P with disease state is presented in Fig. 3. The primary
measure of the diagnostic eYciency of the algorithm, area
under the ROC (AUCA), is presented in Table 5 and com-
pared with that of CA-125 alone (AUCC). AUCA was sig-
niWcantly greater than AUCC for the validation cohort
(p < 0.01) and early stage cohort (p <0 . 0 1 ) .  T o  a s s e s s  t h e
potential inXuence of age on overall multivariate analysis,
age-adjusted modelling and validation were performed. The
data derived were not statistically signiWcantly diVerent
from non-age adjusted.
Secondary outcome measures
Estimates of the sensitivity and speciWcity for CA-125 (at a
threshold value ¸35 U/ml) and biomarker panel (at thresh-
old values of 0.3 and 0.5) are presented in Table 6 for the
validation and early stage cohorts. The relationship
between P and disease stage is presented in Fig. 4. No
signiWcant eVect of tumor type on P was identiWed
(p > 0.05, Kruskal–Wallis test, data not shown).
Second-site conWrmation of predicted posterior probability 
values
Study samples were re-assayed in a second laboratory by an
independent operator (GB). Data obtained were subjected
to multivariate modelling and the P values derived were
compared with those obtained from the primary site. No
statistically signiWcant diVerences in P values derived
from data from the two laboratories were identiWed by
paired two samples analysis (p >0 . 0 5 ) .
Discussion
The primary objective of this study was to test the hypothe-
sis that the area under the ROC curve for a multimarker
ovarian cancer panel (CA-125 and acute phase response
proteins: CRP, SAA, IL-6 and IL-8) was signiWcantly
greater than that observed for CA-125 alone. A phase II Fig. 2 ROC curves for individual biomarkers and multivariate model
Fig. 3 Predicted posterior probabilities (P the probability of a sam-
ple belonging to the case group) are presented for controls and cases
within the validation and early stage cohorts. Median values are repre-
sented by horizontal lines. Control versus case comparisons (Mann–
Whitney test) for all cohorts were signiWcantly diVerent (p <0 . 0 1 )
Table 5 Comparison of the area under the curve of the receive opera-
tor characteristic curves for CA-125 alone and the multianalyte panel
within the validation cohort
Validation 
cohort
Early stage 
cohort
CA-125 0.960 0.937
Multianalyte 0.988 0.985
AUCA-AUCC (%) 2.8 4.8
Mann–Whitney 
test p (two-tailed)
p <0 . 0 1 p <0 . 0 1J Cancer Res Clin Oncol (2010) 136:1079–1088 1085
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biomarker trial (a retrospective, case–control study) that
involved 362 patient samples was conducted to test this
hypothesis.
All biomarkers were signiWcantly elevated in association
with ovarian cancer, however, individually none of the
biomarkers displayed greater diagnostic performance than
CA-125. With respect to the area captured under the ROC
curves by individual biomarkers, CA-125 > SAA >
CRP > IL-8 > IL6. When biomarker data were used to gen-
erate a multivariate classiWcation model, the P values
from the biomarker panel captured 0.988 of the area under
the ROC curve which was signiWcantly greater than that
observed for CA-125 alone (0.960, p < 0.01). When applied to
early stage cases alone (i.e. Stages I and II), the performance of
the biomarker panel was similar (0.985) however, CA-125
performance decreased to 0.937 (p < 0.01), data consistent
with an increased diagnostic eYciency of the multimarker
panel for early stage ovarian cancer.
The area under the ROC curve was used as the primary
statistical endpoint as this parameter is considered less sus-
ceptible to variations in mix of true positive and negative
samples within the study cohort.
A measure of the reproducibility of biomarker panel per-
formance was obtained by the re-assay of study samples in
a second laboratory by an independent operator. The P
values obtained from both laboratories were not signiW-
cantly diVerent.
The concentration of analytes reported in this study for
controls and cases are comparable with those previous pub-
lished (Geisler et al. 1996; Johnson et al. 2008; Kodama
et al. 1999; Lambeck et al. 2007; Maccio et al. 1998; Mosh-
kovskii et al. 2005a; Woolas et al. 1993). The diagnostic
eYciency of CA-125 within the study cohort (all FIGO
stages) was 91.1%. The diagnostic eYciency of CA-125 for
ovarian cancer has been previously reported between 70
and 90% (Park et al. 1995; Saraswathi and Malait 1995;
Visintin et al. 2008).
All biomarkers utilised in the panel have been previously
associated with ovarian cancer. Bertenshaw et al. ( 2008)
reported CRP and IL-8 concentrations as being amongst the
most informative ovarian cancer serum biomarkers in a
multianalyte proWling study. Similarly, IL-6 and IL-8 have
been reported to be elevated in serum of patients with ovar-
ian cancer (Darai et al. 2003; Lambeck et al. 2007; Lokshin
et al. 2006) and utilised in multimarker panels for the detec-
tion of ovarian cancer (Gorelik et al. 2005). In the latter
study, IL-6 and IL-8 were used in combination with other
cytokines and CA-125 in a classiWcation tree analysis to
deliver a test with greater sensitivity and speciWcity than
Fig. 4 Association between ovarian cancer disease stage and pre-
dicted posterior probabilities. Median values are represented by hori-
zontal lines. Control versus case comparisons (Mann–Whitney test) for
all cohorts were signiWcantly diVerent (p <0 . 0 1 )
Table 6 Contingency tables for 
multianalyte diagnostic 
(threshold P ¸ 0.3 and 
P ¸ 0.5) and CA-125 alone 
(threshold > 35 U/ml)
Cohort Test State Predicted state Success rate
Disease No disease
Validation cohort CA-125 Case 63 5 92.6
Control 12 103 89.6
Multianalyte P ¸ 0.3 Case 64 4 94.1
Control 10 105 91.3
Multianalyte P ¸ 0.5 Case 63 5 92.6
Control 7 108 93.9
Early stage cohort CA-125 Case 35 4 89.7
Control 12 103 89.6
Multianalyte P ¸ 0.3 Case 36 3 92.3
Control 10 105 91.3
Multianalyte P ¸ 0.5 Case 35 4 89.7
Control 7 108 93.91086 J Cancer Res Clin Oncol (2010) 136:1079–1088
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CA-125 alone. IL-6 and IL-8 are pleiomorphic cytokines
that have been also implicated in aspects of tumor growth,
disease progression and/or treatment (HeXer et al.  2003;
Wang et al. 2005, 2007; Xu and Fidler 2000).
CRP and SAA are major components of the acute phase
response (Pepys and Baltz 1983). Several studies have
reported elevated serum concentrations of CRP in associa-
tion with ovarian cancer (Avall Lundqvist et al.  1989;
HeXer et al. 2008; Kodama et al. 1999; Maccio et al. 1998;
McSorley et al.  2007). Only limited data, however, are
available on SAA concentrations in ovarian cancer patients
(Helleman et al. 2008). Serum concentrations of CRP are
correlated with IL-6 and high concentration has been
reported to be a signiWcant factor in prognosis of ovarian
cancer (Kodama et al. 1999; Maccio et al. 1998). Indeed,
high CRP is reportedly a risk factor for developing ovarian
cancer (McSorley et al. 2007).
In 2005, Moshkovskii et al. (2005b) identiWed two forms
of SAA using SELDI-TOF mass-spectrometry. The authors
provided evidence that the presence of both forms in 55%
of ovarian cancers compared to only 6% of healthy controls
indicative that an N-terminal truncated form of SAA may
be signiWcant for diagnosis. SAA was further identiWed in a
proteomic study by Helleman et al. (2008) as a potential
marker for monitoring of disease progression, where in
combination with CA-125 and seven other markers, a sensi-
tivity of 91–100% was achieved. CRP and SAA have been
implicated in a range of neoplastic diseases (Weinstein
et al. 1984).
The data obtained in this study are consistent with and
support previous observations of the association between
elevated acute phase proteins and the presence of ovarian
cancer. When such biomarkers are used in combination
with CA-125, diagnostic eYciency for ovarian cancer is
increased overall (validation cohort) and for early stage dis-
ease (early stage cohort). At P values of 0.3–0.5, the bio-
marker panel delivers a balance between sensitivity and
speciWcity, and displays a false positive rate of 6–8%. At
this level of performance, while the biomarker panel would
reduce by 30–50% the number of women misdiagnosed
with cancer by CA-125, it would not be suitable as a
screening modality.
The study reported herein is a retrospective, case–con-
trol design and the diagnostic performance parameters
reported cannot be extended beyond the context of the
study. Additional studies, therefore, are required to assess
the clinical utility of such multimarker tests within both
high-risk cohorts (including women with a genetic predis-
position to ovarian cancer) and within the general popula-
tion (where reliable estimates of positive and negative
predictive values may be obtained) (Coates et al.  2008).
The utility of biomarker panels for the diagnosis of ovarian
cancer, such as that reported herein, may be further
enhanced if used in a multimodal approach, for example, in
combination with a symptom index as recently described
by Andersen et al. (2008).
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